Neuroimaging
29
5
7
17
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 29 trials
100.0%
+13.5% vs benchmark
3%
1 trials in Phase 3/4
6%
1 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (29)
Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial
Evaluation of the Implementation of the Hemispheric Dominance During Development
Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope
Neural and Physiological Correlates of Psychedelic Sub-states
Fast Brain MRI in Children With Suspected Brain Tumor
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)
Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
Rural Autistic Individuals - Supporting Expression
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
Early Diagnosis of SCD Based on Radiogenomics
Intervention of Intestinal Microorganism in Mild Cognitive Impairment
Lorazepam Effects on Neuroimaging Measures
The Difference of Grey Matter Volume Among the Patients of Schizophrenia
Long-term Consequences of Neuroimaging and Perceived Cognitive Dysfunction in oPRES
Comparing Brain Images Before and After MRI-upgrade - TimFit Upgrade Study
Mindful Self-Regulation fMRI Pilot Study
Vehicle Automation Impact on Drivers
The Study of Acupuncture on Vascular and Functional Neuroimaging in Parkinson's Disease Patients With Sleep Disorders